Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: musculoskeletal disease

New Musculoskeletal Ultrasound Course

  |  

The ACR is broadening its educational offerings in musculoskeletal ultrasound by holding its first stand-alone musculoskeletal ultrasound course for rheumatologists this August in Chicago. The same course will be offered prior to the 2010 ACR/ARHP Annual Scientific Meeting.

Help Patients with Scleroderma Manage Musculoskeletal and Functional Limitations

  |  

On March 10, Janet Poole, PhD, OTR, professor of the occupational therapy graduate program at the University of New Mexico in Albuquerque, will continue the ARHP’s Audioconference/Webcast Series with the management of scleroderma. Dr. Poole received her BS in occupational therapy from Colorado State University, her MA degree in educational psychology from the University of North Carolina, Chapel Hill, and her PhD in motor learning/motor control from the University of Pittsburgh. Dr. Poole’s research interest is in scleroderma and the functional impact of the disease on the tasks of daily living, oral hygiene, parenting, and employment. She has conducted a number of studies examining rehabilitation interventions with people who have scleroderma and, with a colleague, is developing a self-management program for these patients. She has also authored several textbook chapters on rehabilitation for people with scleroderma.

Biologic Logic: Making Sense of Current Therapies for Rheumatic Diseases

  |  

Continuing the ARHP 2009 Audioconference/Webcast series, Daniel F. Battafarano, DO, FACP, FACR, will discuss the use of biologic therapy in the treatment of rheumatology patients on February 10 from noon to 1:00 pm ET. During the session, Dr. Battafarano will review basic immunology, inflammation, and relevant cytokines for common rheumatic diseases. In addition, he will describe the current biologic therapies and their relationship to rheumatic disease outcomes, and identify future biologic strategies for therapy.

Genetic Influence on OA

  |  

In 59,970 twins aged 35 years or older, Magnusson et al. compared how much genetics contributes to osteoarthritis (OA) with the genetic contribution to other rheumatic/musculoskeletal diseases (RMDs) in the same population, while exploring the role of shared genetics in OA and other RMDs. The researchers used data from the Swedish Twin Registry, in addition to the Swedish National Patient Register. They concluded that the heritability (i.e., the total genetic contribution to a trait) of OA is relatively large compared with other rheumatic musculoskeletal diseases.

Glucocorticoid Use at Any Dose Increases Fracture Risk

  |  

The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.

How to Optimize Treatment for Aging Patients with Rheumatic Conditions

  |  

As patients with rheumatic musculoskeletal disease age, the number of medications they take may increase (i.e., polypharmacy), which can result in unwanted side effects and serious adverse effects. Lee et al. offer considerations and insights into caring for aging patients in a polypharmacy situation to better meet their health and lifestyle needs.

Glucocorticoid Use May Result in Loss of Bone Mineral Density

  |  

Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.

2022 ACR Guideline for Vaccinations in Patients with RMDs

  |  

This guideline provides evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases. It includes expanded indications for some vaccines, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy.